COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

An Open-Label, Multi-Center, Phase Ib/II Study Evaluating The Safety And Efficacy Of AUTO1, A CAR T Cell Treatment Targeting CD19 In Adult Patients With Relapsed Or Refractory B Cell Acute Lymphoblastic Leukemia

Protocol No
AUTOLUS-ALL-CAR-T-CD-19
Principal Investigator
Sameem Abedin
Phase
II
Summary
To find out whether the investigational drug AUTO1 reduces the symptoms of lymphoblastic leukemia, and whether it causes any side effects.
Description
Auto 1 in relapsed or refractory B-ALL
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL